Entries Written By Brad McCarty
The American College of Cardiology’s Scientific Session is an annual event that draws physicians, vendors, startups, and subject matter experts from across the United States. For the past two years, AngelMD has had the privilege of hosting the ACC’s Innovation Challenge. The Innovation Challenge pits a pool of startup contestants against one another in a Shark Tank-style pitch competition, where the teams compete for a pool of prizes.
This year’s competition was broken into two categories: Artificial Intelligence, and Digitally-Enabled Medical Devices. Given AI’s rise of importance in healthcare, the ACC wanted to give companies who make heavy use of AI the opportunity to showcase what they have accomplished, and what they’re planning for the future. The teams that were chosen to compete came from the AngelMD network, and were scored not only by AngelMD but also by member-physicians of the ACC.
- Care Angel
- Moving Analytics
- Sira Medical
Moving Analytics was chosen as the winner from the Artificial Intelligence category. Their pitch showed a strong understanding of the market, its challenges, and a viable way toward solving them.
For heart disease patients, cardiac rehabilitation is a proven method of preventing readmission. Unfortunately, a lack of convenient options for patients means that a mere 15 percent of them ever complete CR programs. Moving Analytics helps hospitals implement virtual CR and secondary prevention programs for cardiac patients. In a value-based care world, where readmission can lead to stiff penalties, it’s critical that patients have access to care that it not only effective, but also considerate of their constraints.
HeartHero was chosen as the winner from the Medical Device category. The company pitched its ultra-portable, affordable, user-friendly AED to the crowd at the ACC.19 Innovation Challenge. A product that can readily save lives, and is available at a lower cost than the status quo was obviously a big hit with the audience.
The use of an AED at the time of an SCA event significantly increases the chance of survival, but currently, AEDs are only used in a small fraction of cases of out-of-hospital SCAs. This gap exists because 70% of out-of-hospital SCA events occur at home, but AEDs are only currently readily available to businesses and institutions. The HeartHero team sees an incredible opportunity to bridge this gap and create a consumer-friendly solution to address these in-home SCA events.
Our congratulations to both teams for their performance, and for winning the Innovation Challenge. Be on the lookout for a full-length article, featuring both companies, that will appear in an upcoming issue of ACC’s Cardiology magazine.
The ultimate goal of AngelMD is to facilitate improved outcomes for startups, investors, and ultimately for patients. Today we are proud to share the news that Saranas, an AngelMD portfolio company, has obtained FDA clearance for its Early Bird Bleed Monitoring system.
A recent study of over 17,000 large-bore transcatheter interventions showed that nearly one in five patients experience a bleeding-related complication. Saranas’ novel early-detection system addresses an unmet need for real-time detection and monitoring of these problems. The company’s last funding raise, in which AngelMD was also a proud investor, allowed for Saranas to submit the De Novo application to the FDA and launch a multi center clinical pilot within the United States.
Saranas originated from the Texas Heart Institute at the Texas Medical Center. Its goal is to provide real-time monitoring without the need for radiation, and at a lower cost than the status quo.
The Early Bird Bleed Monitoring System is now being piloted across multiple centers to assess its versatility, and to increase patient safety. The company plans to launch the system commercially in selected centers across the US.
AngelMD is joining forces with the American College of Cardiology to bring you the ACC19 Innovation Challenge, as part of the ACC.19 Annual Scientific Sessions in New Orleans, Louisiana. This year, the focus is on Artificial Intelligence and Digitally-Enabled Medical Devices. We will be doing a deep dive into each of the winning companies, to be published in ACC’s Cardiology magazine.
On top of being featured in Cardiology, each winner will also receive the following:
- A $5,000 credit toward a structured investment syndicate through AngelMD
- A commemorative plaque presented by the ACC
- Complimentary turnkey kiosk space at the ACC.20 Future Hub
- Complimentary exhibit space at the ACC.20 Expo
Artificial intelligence (and relatedly, machine learning) is a hotbed topic for healthcare right now. With major medical names entering the ring, as well as companies like Apple and Amazon, AI is primed to be the topic to watch in the years to come. Here are the finalists for the ACC.19 Innovation Challenge:
Likewise, digitally-enabled medical devices are seeing some of the highest levels of investment activity. We’ve finally moved well-beyond smart watches and into a world where conditions such as hemodialysis and sudden cardiac arrest can be more closely monitored and treated through medical devices. These are the finalists from the Digitally-Enabled Medical Device category.
Join us for the ACC.19 Innovation Challenge, March 17th and 18th at the ACC’s 68th annual expo. Can’t make it to the expo? Be sure to follow AngelMD on Facebook where we will be announcing the winners as the event happens.
Each of the following startups joined AngelMD in the past month. Check out a new company in a specific innovation category.
VR / AI
Each quarter, AngelMD produces a report that details what’s been happening in the world of private healthcare investment. This Q4 report, rounding out 2018, comes from our individual evaluation of over 500 SEC Form D filings. We have eliminated filings that were not directly involved with healthcare, filings from large, public companies, and those related to private equity buyouts.
The State of Healthcare Funding
As is typical, Q4 saw fewer overall deals than the rest of the year. That said, the total size of all deals grew by nearly $400 million. The median deal size more than doubled from Q1, to $3.77 million. AngelMD analysts believe that, given the market conditions, 2019 is sizing up to be a formidable year for healthcare investment.
A New Challenger
It’s not uncommon to see oncology, bio-pharma, or genomics take the lead for the amount of money raised each quarter. But Q4 brought about quite the surprise. Dermatology and plastics, with a combined total of $563 million, was the sub-specialty with the largest total raise.
Notably, oncology is still the second largest raise in the bio-pharma category, with a total of $547 million. As we delve deeper into CRISPR and other genome areas, we’re also seeing significant numbers from from genome editing, cell therapy, and medical genetics.
AngelMD’s 2018 Story
AngelMD members continued to show strong interest in a wide variety of investments through 2918. As you might expect, California and Texas had the largest number of raises, which coordinates to the number of AngelMD members in those states. Interestingly, neurology was the speciality with the largest amount of money raised in the year.
We look forward to even more investment activity in 2019, and helping to shape the future of healthcare. The full Q4 investment report is available to all members, who are following AngelMD, through their activity feed.